Clinical Trial Update: MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

A Phase II clinical trial is investigating lenalidomide for patients with mild cognitive impairment, and the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix | Conditions: Cognitive Impairment, Mild, Cognitive Dysfunction | Phase 2 | Status: NOT_YET_RECRUITING